PDL BioPharma Inc. [PDLI] saw a change by -1.15% with the Thursday trading session, closing the trade at the price of $3.45. The company is holding 118.33M shares with keeping 113.15M floating shares. With the latest trading session, the stock is set at 67.48% off compared to its 52-week low, sliding -10.62% from high for the same period of time.
Since its 90-day high, the share price saw a move by -10.62%, trading +39.68% in oppose to its 90-day low While during the day, 118.33M shares valued at 273412.0 were bought and sold.
PDL BioPharma Inc. [NASDAQ:PDLI]: Analyst Rating and Earnings
Equities traders oftentimes stay updated on what leading stock market analysts say about a potential stock purchase. When it comes to PDL BioPharma Inc. [PDLI], the most recently available average analyst rating is from the quarter that ends in 12/30/2019. On average, stock market experts give PDLI an Hold rating. The average 12-month price forecast for this stock is $3.45, with the high estimate being $3.00, the low estimate being $3.00 and the median estimate amounting to $3.00. This is compared to its latest closing price of $3.49.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for PDL BioPharma Inc. [PDLI] is sitting at 3.00. This is compared to 1 month ago, when its average rating was 3.00.
Keep looking out for the next-scheduled quarterly financial results that this company is expected to put out, which is slated to occur on 08/05/2020.
Fundamental Analysis of PDL BioPharma Inc. [PDLI]
Now let’s turn to look at profitability: its Gross Margin at 2.10%.
This company’s Return on Total Capital is -9.01, and its Return on Invested Capital has reached -9.54. Its Return on Equity is -10.90%, and its Return on Assets is -8.30%. These metrics suggest that this PDL BioPharma Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
Turning to investigate this organization’s capital structure, PDL BioPharma Inc. [PDLI] has generated a Total Debt to Total Equity ratio of 4.88. Similarly, its Total Debt to Total Capital is 4.65, while its Total Debt to Total Assets stands at 4.04. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 4.72, and its Long-Term Debt to Total Capital is 4.50.
What about valuation? This company’s Enterprise Value to EBITDA is -3.48. The Enterprise Value to Sales for this firm is now 3.59, and its Total Debt to Enterprise Value stands at 0.13. PDL BioPharma Inc. [PDLI] has a Price to Book Ratio of 0.68.
PDL BioPharma Inc. [PDLI] has 118.33M shares outstanding, amounting to a total market cap of 412.97M. Its stock price has been found in the range of 2.06 to 3.86. At its current price, it has moved down by -10.62% from its 52-week high, and it has moved up 67.48% from its 52-week low.
This stock’s Beta value is currently 0.88, which indicates that it is 4.44% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 62.82. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is PDL BioPharma Inc. [PDLI] a Reliable Buy?
Shares of PDL BioPharma Inc. [PDLI], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.